Thymalfasin for the treatment of chronic hepatitis B

References

• Lee WM. Hepatitis B virus infection. NEngl. Med. 337, 1733 (1997).
   PubMed Web of Science ®Google Scholar
• Nicoll A, Locarnini S. Present and future directions in the treatment of chronic hepatitis B infection. j Gastroenterol. Hepatol. 12, 843–854 (1997).
   Google Scholar
• Chisari FV. Viruses, immunity and cancer: lessons from hepatitis B. Am. J. Path. 156, 1118–1132 (2000).
   Web of Science ®Google Scholar
• Liaw YE Tsai SL. Pathogenesis, and clinical significance of acute exacerbations and remissions in patients with chronic hepatitis B virus infection. Vira Hep. Rev. 3,143-154 (1997)40.
   Google Scholar
• Liaw YE, Chu CM, Su IJ, etal. Clinical and histological event preceding hepatitis B e antigen seroconyersion in chronic type B hepatitis. Gastroenterology 84, 216–219 (1983).
   Google Scholar
• Hsu YS, Chien RN, Yeh CT, etal. Long-term outcome following spontaneous HBeAg seroconyersion in patients with chronic hepatitis B. Hepatology35, 1522–1527 (2002).
   Google Scholar
• Liaw YE Therapy of chronic hepatitis B:current challenges and opportunities. J Viral Hep. 9, 393–399 (2002).
   PubMed Web of Science ®Google Scholar
• Conjeeyaram HS, Lok ASE Management of chronic hepatitis B. J Hepatol. 38, S90—S103 (2003).
   Google Scholar
• Manesis EK, Hadziyannis SJ. Interferon-a treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 121, 101–109 (2001).
   PubMed Web of Science ®Google Scholar
• Liaw YF, Tsai SL, Chien RN, et al. Prednisolone priming enhances Thl response and efficacy of subsequent lamiyudine therapy in patients with chronic hepatitis B. Hepatology32, 604–609 (2000).
   Google Scholar
• Liaw YF, Corticosteroid priming in interferon therapy of chronic hepatitis B virus infection. Interferon Cytokines 25, 17–20 (1994).
   Google Scholar
• Sheen IS, Liaw YF, Lin SM, Chu CM. Severe clinical rebound upon withdrawal corticosteroid before interferon therapy: incidence and risk factors. J Gastroenterol. Hepatol. 11, 143–147 (1996).
   PubMed Web of Science ®Google Scholar
• Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamiyudine for chronic hepatitis B. N Engl. J Med. 339, 61–68 (1998).
   PubMed Web of Science ®Google Scholar
• Dienstag JL, Schiff ER, Wright TL, etal. Lamiyudine as initial treatment for chronic hepatitis B in the United State. N. Engl. J. Med. 341, 1256–1263 (1999).
   PubMed Web of Science ®Google Scholar
• Schalm SW, Heathcote J, Cianciara J, et al. Lamiyudine and interferon-a combination treatment of patients with chronic hepatitis B infection: a randomized trial. Gut 46, 562–568 (2000).
   PubMed Web of Science ®Google Scholar
• Liaw YF, Leung NW, Chang TT, et al. Effects of extended lamiyudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 119, 172–180 (2000).
   Google Scholar
• Leung NW, Lai CL, Chang TT, et al. Extended lamiyudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconyersion rates: results after 3 years of therapy. Hepatology33, 1527–1532 (2001).
   Google Scholar
• Chien RN, Liaw YE Atkins M.Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconyersion during lamiyudine therapy in patients with chronic hepatitis B. Hepatology30, 770–774 (1999).
   Google Scholar
• Tassopoulos NC, Volpes R, Pastore G, et al. Efficacy of lamiyudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology29, 889–896 (1999).
   Google Scholar
• Honkoop P, de Man RA, Niesters HG, Zonderyan PE, Schalm SW. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamiyudine therapy. Hepatology32, 635–639 (2000).
   Google Scholar
• Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. Hepatitis B e antigen seroconyersion after lamiyudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology32, 803–806 (2000).
   Google Scholar
• Liaw YE Impact of YMDD mutations during lamiyudine therapy in patients with chronic hepatitis B. Antiviral Chem. Chernother. 12, S67—S71 (2001).
   Google Scholar
• Low TL, Goldstein AL. Thymosins: structure, function and therapeutic applications. Thymus 6, 27–42 (1984).
   PubMedGoogle Scholar
• Billich A. Thymosin-al SciClone Pharmaceuticals. Carr. Opin. Invest. Drugs 3, 698–707 (2002).
   PubMedGoogle Scholar
• Thymalfasin package insert. SciClone Pharmaceuticals International, CA, UK (1998).
   Google Scholar
• Ancell CD, Phipps J, Young L. Thymosin-al. A177. J. Health Syst. Pharm. 58, 879–888 (2001).
   Google Scholar
• Weller FE, Shah U, Cummings GD, Chretien PB, Mutchnick MG. Serum levels of immunoreactiye thymosin-al and thymosin B4 in large cohorts of healthy adults. Thymus 19, 45–52 (1992).
   PubMedGoogle Scholar
• Rost KL, Wierich W, Masayuki F. Tuthill CW, Horwitz DL, Herrmann WM. Pharmacokinetics of thymosin-al after sc. injection of three different formulations in healthy volunteers. Int. J Can. Pharrnacol. Ther. 37, 51–57 (1999).
   Web of Science ®Google Scholar
• Sztein MB, Serrate SA, Goldstein AL. Modulation of interleukin-2 receptor expression on normal human lymphocytes by thymic hormones. Proc. Nat] Acad. Sci. USA 83, 6107–6111 (1986).
   PubMed Web of Science ®Google Scholar
• Serrate SA, Schulof RS, Leonidas L, Goldstein AL, Sztein MB. Modulation of human natural killer cell cytotoxic activity, lymphokine production and interleukin-2 receptor expression by thymic hormones. j II77177111701 139, 2338–2343 (1987).
   Google Scholar
• Baxavanis CN, Recios GJ, Perez S, Kokkinopoulos D, Papamichail M. Immunoregulatory effects of fraction 5 thymus peptide-thymosin-al enhances while thymosin B4 suppresses the human autologous and allogeneic mixed lymphocyte reaction. immunopharrnaco/. 13, 133–141 (1987).
   PubMed Web of Science ®Google Scholar
• Glullani C, Napolitano G, Mastino A, et al. Thymosin-al regulates MHC class I expression in FRTL-5 cells at transcriptional level. Eur. j Immunol. 30, 778–786 (2000).
   PubMed Web of Science ®Google Scholar
• Knutsen AP, Freeman JJ, Mueller KR, Roodman ST, Bouhasin JD. Tymosin-al stimulates maturation of CD34 stem cells into CD3.4 cells in an in vitro thymic epithelia organ coculture model. Int. J ImmunopharmacoL 21, 15–26 (1999).
   PubMed Web of Science ®Google Scholar
• Baumann CA, Badamchian M, Goldstein AL. Thymosin-al antagonized dexamethasone and CD3-induced apoptosis of CD4. CD8 thymocytes through the activation of camp and protein kinase C dependent second messenger pathway. Mech. Ageing Dev. 94, 85–101 (1997).
   PubMed Web of Science ®Google Scholar
• Mutchnick MG, Appelman HD, Chung HT, etal. Thymosin treatment of chronic hepatitis B: a placebo-controlled pilot trial. Hepatology14, 409–415 (1991).
   Google Scholar
• Moshier JA, Mutchnick MG, Dosescu J, et al. Thymosin-al but not interferon-a, specifically inhibits anchorage-independent growth of hepatitis B viral transfected HepG2 cells. J HepatoL 25, 814–820 (1996).
   PubMed Web of Science ®Google Scholar
• Germ JL, Korba BE, Cole PJ, Tennant BC. A preliminary report of a controlled study of thymosin-al in the woodchuck model of hepadnayirus infection. Adv. Exp. Med. Biol. 312, 121–123 (1992).
   PubMedGoogle Scholar
• Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T-cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins.II77177111701. 136, 2348–2357 (1986).
   Google Scholar
• Koziel MJ. Cytokines in viral hepatitis.Sentin. Liver Dis. 19, 157–169 (1999).
   PubMed Web of Science ®Google Scholar
• Andreone P, Cursaro C, Gramenzi A, et al. ••In vitro effect of thymosin-al andinterferon-a on Thl and Th2 cytokine synthesis in patients with chronic hepatitis Cf Viral Hepat. 8, 194–201 (2001).
   PubMed Web of Science ®Google Scholar
• Sherman KE, Jones CC, Goldstein AL, Naylor PH. Low thymosin-al concentrations in patients chronically infected with the hepatitis B virus. Viral II77177111701 4, 195–199 (1991).
   Google Scholar
• Andreone P, Cursaro C, Gramenzi A, et al. A randomized controlled trial of thymosin-al versus interferon-a treatment in patients with hepatitis B e antigen antibody-and hepatitis B virus DNA-positive chronic hepatitis B. Hepatology24,774-777 (1996).
   Google Scholar
• Chien RN, Liaw YF, Chen TC, Yeh CT, Sheen IS. Efficacy of thymosin-al in patients with chronic hepatitis B: a randomized, controlled trial. Hepatology27, 1383–1387 (1998).
   Google Scholar
• Mutchnick MG, Lindsay KL, Schiff ER, et al Thymosin-al treatment of chronic hepatitis B: results of a Phase III multicentre, randomized, double-blind and placebo-controlled study. J. Viral Hepat. 6,397–403 (1999).
   PubMed Web of Science ®Google Scholar
• You J, Zhuang L, Zhang B, et al A randomized controlled clinical trial on the treatment of thymosin-al versus interferon-a in patients with hepatitis B. World J. GastroenteroL7, 411–414 (2001).
   Google Scholar
• Zavaglia C, Severini R, Tinelli C, etal. A randomized, controlled study of thymosin-al therapy in patients with antiHBe, HBV DNA-positive chronic hepatitis B. Dig. Dis. Sd. 45,690–696 (2000).
   PubMed Web of Science ®Google Scholar
• Zhuang L, You J, Zhang B, et al. Preliminary results of thymosin-al versus interferon-a treatment in patients with HBeAg negative and serum HBV DNA positive chronic hepatitis B. World J. Gastroentero1.7, 407–410 (2001).
   Google Scholar
• Lau GKK. Use of immunomodulatory therapy (other than interferon) for the treatment of chronic hepatitis B virus infection. J. GastroenteroL Hepatol. 15, E46—E52 (2000).
   Web of Science ®Google Scholar
• Cow WC, Ng KY, Mcscnas S, Law NM, Ng HS. The interim results of thymosin-al in a randomized controlled study in the treatment of chronic hepatitis B patients: Singapore experience. Hepatology28, 586A (1998).
   Google Scholar
• Chan HLY, Tang JL, Tam W Sung JJ. Theefficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysis. Aliment PharrnacoL Ther. 15, 1899–1905 (2001).
   PubMed Web of Science ®Google Scholar
• Liaw YF, Lin SM, Chen TJ, Chien RN, Sheen IS, Chu CM. Beneficial effect of prednisolone withdrawal followed by human lymphoblastoid interferon on the treatment of chronic type B hepatitis in Asians: a randomised controlled trial. j HepatoL 20, 175–180 (1994).
   Web of Science ®Google Scholar
• Lin SM, Sheen IS, Chien RN, Chu CM,Liaw YE Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology29, 971–975 (1999).
   Google Scholar
• Rasi G, Mutchnick MG, Virgilio DD, et al. Combination low-dose lymphoblastoid interferon and thymosin-al therapy in the treatment of chronic hepatitis B. J. Viral Hepat. 3,191–196 (1996).
   PubMed Web of Science ®Google Scholar
• Saruc M, Yuceyar H, Kucukmetin N, Demir MA, Kandiloglu AR. Combination thymosin-al and interferon-a2, in the treatment of antiHbe-positive chronic hepatitis B in Turkey. Hepato-Gastroenterol. 49,798–802 (2002).
   PubMed Web of Science ®Google Scholar
• Saruc M, Ozden N, Turkel N, et al Long-term outcomes of thymosin-al and interferon a-2b combination therapy in patients with hepatitis B e antigen (HBeAg) negative chronic hepatitis B. J. Pharrn. Sci.;92, 1386–1395 (2003).
   Google Scholar
• Lau GKK, Nanji A, Hou J, et al. Thymosin-al and famciclovir combination therapy activates T-cell response in patients with chronic hepatitis B virus infection in immune-tolerant phase. J. Viral Hepat. 9, 280–287 (2002).
   PubMed Web of Science ®Google Scholar
• Suoglu OD, Elkabes B, Sokucu S, Saner G. Thymosin-a and lamivudine combination therapy in pediatric patients with chronic hepatitis B infection unresponsive to previous treatments: a pilot study. Proceedings of the 9th United European Gastroenterology Week. Amserdam, The Netherlands, 6–10 October 2001.
   Google Scholar
• Dikici B, Bosnak M, Haspolat K. The effect of thymosin-al and lamivudinecombination therapy in chronic hepatitis B patients. Indian Pediatr. 39,701–702 (2002).
   PubMedGoogle Scholar
• Liaw YF, Leung N, Guan R, Lau GKK, Merican I. Asian—Pacific consensus statement on the management of chronic hepatitis B: an update. J. Gastroenterol. HepatoL 18,239–245 (2003).
   PubMed Web of Science ®Google Scholar
• Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000 — summary of a workshop. Gastroenterology 120,1828 (2001).
   PubMed Web of Science ®Google Scholar
• Cooksley WG, Piratvisuth T, Lee SD, et al Peginterferon-a2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J. Viral Hepat. 10,298-305 (2003).Affiliations
   Google Scholar